Loading
A phase 2 trial of carboplatin and pemetrexed in lung cancer, run by University Hospital, Essen, now recruiting.
Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR) is a phase 2, interventional study registered as NCT06784791 by University Hospital, Essen, with a registry enrolment figure of 20 participants, started 2024-11-06 and due to reach its primary completion in 2027-07-31. Interventions recorded: Amivantamab Intravenous; Carboplatin/Pemetrexed. Conditions listed: Lung Cancer (NSCLC). Primary outcome: Feasibility of one cycle of preoperative amivantamab therapy. Lung eligibility wording from the registry: ", bronchoscopy-guided biopsy) confirmed non-small-cell lung cancer (NSCLC) eligible for anatomic resection, with the following specifications:". Sites: Belgium, Germany, Netherlands. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin and the tag lung-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/